Recently added

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY

Kuchimanchi, Mita; Jørgensen, Trine Lembrecht; Hanze, Eva; Jain, Angela; Berton, Dominique; André, Thierry; OAKNIN, ANA (Wiley, 2025-03)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

Vitiello, Pietro Paolo; BARDELLI, Alberto; Saoudi Gonzalez, Nadia (Wiley, 2025-02)

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

de la Fuente Vivas, Dalia; CAPPITELLI, VINCENZO; García Gómez, Rocío; Valero Díaz, Sara; Amato, Camilla; Rodriguez, Javier; Duro Sánchez, Santiago; Arribas, Joaquin (Wiley, 2025-02)

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib

Harrison, Claire; mesa, ruben; Talpaz, Moshe; Gerds, Aaron; Perkins, Andrew; Gupta, Vikas; Fox, Maria Laura (Elsevier, 2025-03)

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Ren, Zhenggang; Chon, Hong Jae; Park, Joon Oh; Pressiani, Tiziana; Kim, Jin Won; Macarulla, Teresa (American Society of Clinical Oncology, 2025-02-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY ﻿

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer ﻿

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility ﻿

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib ﻿

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial ﻿

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial